Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
NCT06038396 trial: what clinicians have said so far
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
- NCT06038396 ↗
- Unknown
- RemeGen Co., Ltd.
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT06038396 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06038396 so far
Podcasts, YouTube videos and posts on X and Bluesky we have indexed that name the trial. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X, typically up to 18 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of RC118 in Combination with Toripalimab / RC148 for Patients with Claudin 18.2-Positive, Locally Advanced Unresectable or Metastatic Malignant Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Unknown
- Conditions
- Advanced Solid Tumor
- Interventions
- RC118; Toripalimab; RC148
- Arms
- Part A-RC118 plus Toripalimab · Experimental
- Part B-RC118 plus Toripalimab / RC148 · Experimental
- Enrollment
- 48 (estimated)
- Primary outcomes
- Phase1: Dose limiting toxicity (DLT)
- Phase1/2: Adverse events (AEs)
- Phase1: Maximum tolerated dose(MTD)
- Phase1: Recommended Phase 2 Dose (RP2D)
- Phase 2: Objective response rate (ORR)
- Sponsor
- RemeGen Co., Ltd.
- Start
- Aug 3, 2023
- Primary completion
- Feb 28, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT06038396 · updated Jan 29, 2025